keynote-a18: pembro or placebo with chemoradiotherapy in newly diagnosed high-risk cervical cancer
Published 5 months ago • 149 plays • Length 0:56Download video MP4
Download video MP3
Similar videos
-
1:38
keynote-a18: pembrolizumab chemoradiotherapy improves os in high-risk cervical cancer
-
1:14
keynote-a18: pembrolizumab with chemoradiotherapy for advanced cervical cancer
-
3:15
highlights on pembro crt in high-risk locally advanced cervical cancer: the keynote-a18 study
-
7:18
keynote-826: pembrolizumab chemotherapy vs placebo chemotherapy for cervical cancer
-
26:28
cervical cancer: key data review | 2022 evolution conference
-
6:38
pembrolizumab with chemotherapy as first line for metastatic cervical cancer
-
1:16
keynote 826: pembrolizumab chemo in patients with advanced cervical cancer
-
14:07
regional priorities – seapid perspectives - dr narissara suratannon
-
2:26
keynote-826: pembrolizumab plus chemotherapy for patients with metastatic cervical cancer
-
20:43
emerging opportunities in cervical cancer
-
11:07
posnoc trial - consultation video
-
54:14
catherine behrens - keynote presentation - assessing risk in cervical cancer screening management..
-
25:22
uterus and cervical cancer - new study results
-
3:34
asco 2018 - keynote 158 - keytruda in previously treated, now relapsing patients with sclc